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BACKGROUND: As a prelude to combination studies aimed at resistance reversal, this dose-escalation/dose-expansion study
investigated the selective Src kinase inhibitor saracatinib (AZD0530) in combination with carboplatin and/or paclitaxel.
METHODS: Patients with advanced solid tumours received saracatinib once-daily oral tablets in combination with either carboplatin
AUC 5 every 3 weeks (q3w), paclitaxel 175mgm 2 q3w, paclitaxel 80mgm 2 every 1 week (q1w), or carboplatin AUC 5 plus
paclitaxel 175mgm 2 q3w. The primary endpoint was safety/tolerability.
RESULTS: A total of 116 patients received saracatinib 125 (N¼ 20), 175 (N¼ 44), 225 (N¼ 40), 250 (N¼ 9), or 300mg (N¼ 3).
There were no clear dose-related trends within each chemotherapy regimen group in number or severity of adverse events (AEs).
However, combining all groups, the occurrence of grade X3 asthenic AEs (all causality) was dose-related (125mg, 10%; 175mg,
20%; X225mg, 33%), and grade X3 neutropenia occurred more commonly at doses X225mg. There was no evidence that
saracatinib affected exposure to carboplatin or paclitaxel, or vice versa. Objective responses were seen in 5 out of 44 patients (11%)
receiving carboplatin plus paclitaxel q3w, and 5 out of 24 (21%) receiving paclitaxel q1w.
CONCLUSION: Saracatinib doses up to 175mg with paclitaxel with/without carboplatin showed acceptable toxicity in most patients,
and are suitable for further trials.
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Src is a non-receptor tyrosine kinase involved in control of various
cellular processes, including proliferation, adhesion, and motility
(Wheeler et al, 2009). Src is overexpressed or activated in many
cancers, and clinical evidence suggests that the degree of Src
activity may correlate with cancer stage (Talamonti et al, 1993;
Wiener et al, 2003; Zou et al, 2009). Moreover, in vitro studies have
implicated Src in the development of resistance to cytotoxic cancer
chemotherapy (Masumoto et al, 1999; Boudny and Nakano, 2002;
Pengetnze et al, 2003; Peterson-Roth et al, 2009). Gene expression
profiling has identified several genomic signatures associated with
advanced and chemotherapy-resistant ovarian cancer (Gevaert
et al, 2008; Cancer Genome Atlas Research Network, 2011),
including the Src pathway (Dressman et al, 2007), although
the predictive nature of a Src-related signature has yet to be
conclusively established. Src activity also has an important role in
tumour angiogenesis, and its inhibition has been demonstrated
experimentally to have anti-tumour effects acting through this
mechanism (Han et al, 2006).
Saracatinib (AZD0530) is a potent and selective inhibitor of Src
kinase that has shown anticancer effects as well as synergy with
other therapies, particularly taxanes, in a range of in vitro and
in vivo preclinical models (Van Schaeybroeck et al, 2008; Chen et al,
2009; Green et al, 2009; Hawthorne et al, 2009; Lu et al, 2009). In a
phase I study in patients with advanced solid tumours, saracatinib
monotherapy was tolerated at doses up to 175mg per day, and
demonstrated inhibition of Src activity in tumour tissue at doses of
50mg and above (Baselga et al, 2010). Saracatinib is suitable for
once-daily oral administration and reaches stable plasma concen-
trations after 10–17 days in humans (Baselga et al, 2010).
These results indicate that saracatinib might have the potential
to enhance the clinical anticancer effects of platinum- and/or
taxane-based cytotoxic chemotherapies. The objectives of this
phase I study (clincialtrials.gov identifier NCT00496028) were to
investigate the safety, tolerability, and pharmacokinetics (PK) of
saracatinib, in combination with carboplatin and/or paclitaxel in
patients with advanced solid tumours, and to identify suitable
doses of saracatinib for future chemotherapy combination studies.
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METHODS
Patients
Patients aged X18 years with locally advanced or metastatic solid
tumours suitable for treatment with either carboplatin or paclitaxel
were eligible. Patients had to have a World Health Organization
performance status of 0–2 and life expectancy of 412 weeks.
Patients were excluded if they had haemoglobin p9 g dl 1;
inadequate haematopoietic function (absolute neutrophil count
p1.5 109 per liter, platelet count p100 109 per liter);
inadequate liver function (serum bilirubin X2 times the upper
limit of reference range (ULRR); aspartate (AST) or alanine
aminotransferase (ALT)X2.5 times ULRR (X5 times the ULRR in
the presence of liver metastases)); measured glomerular filtration
rate (GFR) p50mlmin 1; last dose of systemic chemotherapy or
radiotherapy within 4 weeks before first dose of study treatment;
concomitant medication with potent inhibitors or inducers of
CYP3A4; severe or uncontrolled systemic conditions (e.g., inter-
stitial lung disease); significant immunodeficiency; risk of
transmitting HIV, or hepatitis B or C virus; brain metastases or
spinal cord compression unless treated X4 weeks before study
entry, and stable without steroid treatment for 1 week; surgeryp4
weeks before study entry (except placement of vascular access);
concurrent anti-cancer therapy (except stable endocrine therapy);
or if they were pregnant, breast feeding or not willing to practice
barrier contraception.
Study design and treatment
This was a two-part, phase I, multi-centre, open-label study
(Figure 1). The study was carried out in accordance with the
Declaration of Helsinki and Good Clinical Practice. The protocol
and consent forms were approved by appropriate independent
review boards, and all patients gave written informed consent.
Part A was a dose-escalation phase to establish the maximum-
tolerated doses of saracatinib in combination with carboplatin
and/or paclitaxel chemotherapy. Four parallel escalation studies
were initiated with saracatinib once-daily, in combination with:
carboplatin every 3 weeks (q3w), carboplatin plus paclitaxel q3w,
paclitaxel alone q3w, and paclitaxel alone q1w. Chemotherapy was
initiated after a 7 to 10-day run-in period of once-daily saracatinib
monotherapy to ensure that saracatinib had reached steady-state
concentrations. Starting at 125mg, saracatinib doses were assessed
sequentially in cohorts of three patients, with dose escalation
proceeding to the next dose cohort if no dose-limiting toxicity
(DLT) was encountered. To maximise the potential for enhance-
ment of chemotherapy, careful exploration of doses above the
phase I monotherapy maximum-tolerated dose was permitted.
If one patient experienced a DLT, the cohort was expanded to six,
and dose escalation proceeded if no further patients encountered a
DLT. If two or more of a maximum of six evaluable patients
experienced a DLT within a cohort, that dose was considered not
tolerated. Intrapatient dose escalation was not permitted. Patients
were considered evaluable for toxicity if they experienced a DLT
during the DLT-assessment period (Figure 1) or completed this
period with X75% of the planned doses of saracatinib. The
following events were defined as DLTs if considered by the
investigator to be of clinical significance, and to be related to
saracatinib monotherapy or combination therapy: Common
Terminology Criteria (CTC) grade 4 haematological toxicity,
except neutropenia of p6 days duration; grade X3 neutropenia
requiring hospitalisation or with fever X38.5 1C; grade X3
thrombocytopenia associated with non-traumatic bleeding (not
applicable to patients on therapeutic anticoagulation); grade X3
non-haematological toxicity not related to tumour progression,
and despite adequate supportive care (excluding alopecia); grade
X3 vomiting for424 h despite suitable anti-emetics; grade 4 ALT,
AST, or alkaline phosphatase elevations in patients with liver
involvement; and delay of X2 weeks in administration of the
second chemotherapy cycle. Dose-escalation decisions were made
by the safety review committee.
Part B was a dose-expansion phase to further evaluate the
tolerable saracatinib dose established in Part A, in combination
Part A
Part B
Chemotherapy regimen
24-hour PK sampling for carboplatin plus paclitaxel
24-hour PK sampling for saracatinib, caroplatin, and paclitaxel, in combination
24-hour PK sampling for saracatinib alone
DLT assessment period
Chemotherapy regimens
Screening
Saracatinib dose
Screening
Saracatinib
once-daily dosing
Carboplatin
and/or
paclitaxel
Carboplatin
and/or
paclitaxel
Chemotherapy
cycle 3, 4, 5 . . . 
21 days
Chemotherapy
cycle 2 
21 days
Chemotherapy
cycle 1 
21 days
Saracatinib
monotherapy
7–10 days
•  125 mg
•  175 mg
•  225 mg
•  250 mg
•  300 mg
•  225 mg
•  Carboplatin AUC 5 (GFR measured)
    plus paclitaxel 175 mg m–2 q3w
•  Carboplatin AUC 5 (GFR measured) q3w
•  Paclitaxel 175 mg m–2 q3w
•  Carboplatin plus paclitaxel q3w
•  Paclitaxel 80 mg m–2 q1w for 3 weeks
Saracatinib doses
Carboplatin
and/or
paclitaxel
Saracatinib
once-daily dosing
from day 3
Carboplatin
plus
paclitaxel
Chemotherapy
cycle 3, 4, 5 . . .
21 days
Chemotherapy
cycle 2
21 days
Chemotherapy
cycle 1
21 days
Carboplatin
plus
paclitaxel
Carboplatin
plus
paclitaxel
Figure 1 Study design.
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with carboplatin plus paclitaxel. In Part B, saracatinib was started 3
days after the cycle-1 chemotherapy infusions to allow assessment
of saracatinib and carboplatin-plus-paclitaxel PK individually and
in combination (Figure 1).
Saracatinib was administered once daily as oral tablets
(strengths 50 and 125mg). Carboplatin AUC 5, based on measured
GFR derived using 51Cr EDTA (edetic acid), was administered as
an i.v. infusion over approximately 1 h. Paclitaxel was adminis-
tered iv over 3 h for doses of 175mgm 2 (q3w), and over 1 h for
doses of 80mgm 2 (every 1 week (q1w)). After the first 21-day
cycle, chemotherapy doses could be reduced successively
by one dose level if toxicities were encountered. Patients continued
to receive chemotherapy in combination with saracatinib until
occurrence of unacceptable toxicity or tumour progression.
Patients who discontinued chemotherapy in the absence of disease
progression continued on single-agent saracatinib at the same
dose as they had been assigned in combination.
Assessments
Adverse events (AEs) were recorded throughout the study period
and for 30 days after the last dose of study treatment, using CTC
for AEs version 3.0. Serum creatinine levels were measured to
investigate the possibility that saracatinib increases creatinine
levels without affecting measured GFR; the results of this analysis
will be presented separately.
Baseline radiological tumour assessment was carried out p4
weeks before the start of treatment. Tumour response was assessed
according to RECIST version 1.0, before dosing of cycle 3, and
approximately every 9 weeks thereafter, until withdrawal from
the study. All analyses were descriptive.
Blood samples for determination of PK parameters in Part B
were taken over a 24-h period, starting immediately pre-infusion
and/or pre-dose on day 1 of cycles 1 and 2, and pre-dose on day 21
of cycle 1 (Figure 1), and subsequently at 2, 4, 6, 8, and 24 h for
saracatinib assessment; and at 3, 3.5, 4, 5, 8, 10, and 24 h for
carboplatin and paclitaxel assessment. Carboplatin in heparinised
human plasma was determined as platinum equivalents using a
validated inductively coupled plasma atomic emission spectro-
scopy method at Eurofins Medinet B.V., Breda, The Netherlands.
Concentrations of paclitaxel in human plasma were determined
using a validated liquid–liquid extraction followed by HPLC-MS/
MS at PRA International, Assen, The Netherlands. Concentrations
of saracatinib in human plasma were determined using a validated
solid-phase extraction followed by HPLC-MS/MS at PRA
International.
RESULTS
Patient characteristics and disposition
A total of 116 patients were treated with saracatinib: 96 in Part A
and 20 in Part B. Patients had various primary tumour types
(Table 1). Thirteen patients discontinued study treatment during
the saracatinib monotherapy run-in period in Part A, and did not
receive chemotherapy; the main reasons being AEs (N¼ 6) and
disease progression (N¼ 5). Saracatinib doses of 125, 175, 225, 250,
and 300mg were evaluated in Part A (Table 2), and a dose of
225mg was evaluated in Part B. The most common reasons for
discontinuation from the study were disease progression (52%),
followed by AEs (37%).
Table 1 Patient characteristics
Part A
Part B Total
Saracatinib with
CþP q3w (N¼ 24)
Saracatinib with
C q3w (N¼21)
Saracatinib with
P q3w (N¼ 27)
Saracatinib with
P q1w (N¼ 24)
Saracatinib with
CþP q3w (N¼20)
All patients
(N¼ 116)
Mean age, years (range) 59 (41–77) 55 (26–71) 61 (41–75) 59 (38–71) 59 (34–73) 59 (26–77)
Sex female/male, N 10/14 14/7 14/13 15/9 6/14 59/57
Primary tumour, N (%)
Ovary 4 (17) 5 (24) 2 (7) 5 (21) 2 (10) 18 (16)
Oesophagus 2 (8) 0 3 (11) 4 (17) 3 (15) 12 (10)
Colorectal carcinoma 4 (17) 4 (19) 1 (4) 1 (4) 1 (5) 11 (9)
Skin/soft tissue 2 (8) 1 (5) 3 (11) 0 5 (25) 11 (9)
Lung 2 (8) 2 (10) 2 (7) 2 (8) 0 8 (7)
Stomach 0 1 (5) 3 (11) 3 (13) 1 (5) 8 (7)
Breast 1 (4) 1 (5) 2 (7) 1 (4) 2 (10) 7 (6)
Prostate 2 (8) 0 0 0 3 (15) 5 (4)
Pancreas 1 (4) 0 1 (4) 1 (4) 1 (5) 4 (3)
Other 6 (25) 7 (33) 10 (37) 7 (29) 2 (10) 32 (28)
WHO performance status, N (%)
0 7 (29) 7 (33) 10 (37) 10 (42) 8 (40) 42 (36)
1 15 (63) 13 (62) 14 (52) 12 (50) 12 (60) 66 (57)
2 2 (8) 1 (5) 3 (11) 2 (8) 0 8 (7)
Number of previous chemotherapy regimens
Mean±s.d. 3.2±1.9 5.0±3.8 3.2±2.6 2.7±2.2 3.6±2.9 3.5±2.8
Median (range) 3 (1–8) 4 (1–15) 2 (1–9) 2 (1–9) 3 (1–12) 3 (1–15)
Previous treatment, N (%)
Surgery 20 (83) 18 (86) 21 (78) 18 (75) 18 (90) 95 (82)
Chemotherapy 22 (92) 21 (100) 26 (96) 24 (100) 19 (95) 112 (97)
Radiotherapy 12 (50) 4 (19) 14 (52) 10 (42) 10 (50) 50 (43)
Immunotherapy/hormone therapy 6 (25) 7 (33) 4 (15) 5 (21) 7 (35) 29 (25)
Other therapy 7 (29) 8 (38) 3 (11) 2 (8) 5 (25) 25 (22)
Abbreviations: C¼ carboplatin; P¼ paclitaxel.
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Dose escalation and dose-limiting toxicities
Of the 83 patients who received saracatinib in combination with
chemotherapy in Part A, 68 were evaluable for DLTs (Table 2).
Fifteen patients were non-evaluable for DLTs, because of
discontinuation due to AEs, considered by the investigator to be
unrelated to saracatinib (N¼ 7), disease progression (N¼ 6), or
voluntary discontinuation (N¼ 2). At the 175-mg dose, the safety
review committee decided to expand two cohorts (carboplatin q3w
and paclitaxel q1w) to at least six evaluable patients, to further
evaluate the safety and tolerability of these dose combinations.
Overall, seven patients experienced a DLT in the first cycle
(Table 2), comprising grade 3 fatigue (1 case), grade 3
hyponatraemia (1 case), grade 3 neutropenia (1 case), grade 3/4
febrile neutropenia (2 cases), grade 5 neutropenic sepsis (1 case),
and grade 3 colitis (1 case—involving pre-existing disease).
Duration of treatment
The chemotherapy regimen associated with most 3-weekly
cycles in combination with saracatinib was paclitaxel q1w
(Supplementary Figure 1). Across chemotherapy regimens, the
number of chemotherapy cycles and the mean actual saracatinib
exposure declined continuously with increasing saracatinib dose
(Supplementary Table 1).
Tolerability
Irrespective of causality, dose, and combination, the most common
AEs were nausea and fatigue, which were reported by more than
half the patients overall (Table 3). Although there were no clear
saracatinib dose–response effects within each chemotherapy arm
for number or severity of AEs, there were some trends overall.
Asthenic AEs of CTC grade X3 (comprising asthenia, fatigue,
lethargy, malaise, mobility decreased, muscular weakness, and
somnolence) occurred more commonly at saracatinib doses
X225mg than at saracatinib doses p175mg (33 vs 17%,
respectively). Adverse events of neutropenia of CTC grade X3
(comprising neutropenia, febrile neutropenia, and neutropenic
sepsis) occurred more commonly at saracatinib doses X225mg
than at saracatinib doses p175mg (37% vs 16%, respectively).
Febrile neutropenia/neutropenic sepsis was reported in a total of
six patients (5%), all of whom received paclitaxel-containing
chemotherapy, and five of whom received saracatinib X225mg.
The proportion of patients with febrile neutropenia/neutropenic
sepsis was higher in Part B (15%) than in Part A (3%).
Adverse events of CTC gradeX3 hyponatraemia were reported in
9 of 65 patients (14%) in carboplatin-treatment groups, compared
with none of 51 patients in non-carboplatin-treatment groups. The
incidence of hyponatraemia did not appear to be related to the dose
of saracatinib. An interim review of laboratory values showed that
most patients with hyponatraemia during the study also had low
sodium at baseline. A protocol amendment was introduced for
Part B to exclude enrolment of patients with sodium
o135mmol l 1, and the incidence of hyponatraemia declined
substantially (Table 3). Hypokalaemia of CTC grade X3 occurred
in six patients overall, and was commonly associated with
vomiting or diarrhoea.
Forty patients (34%) experienced an AE leading to discontinua-
tion of saracatinib. No single event dominated as a reason for
discontinuation. There were 15 deaths on study; 14 attributed by
the investigator to disease, and 1 attributed to an AE of
neutropenic sepsis considered related to saracatinib and paclitaxel.
In 2 of the 14 deaths attributed to disease, a contribution from an
AE considered related to saracatinib was reported as follows:
respiratory failure as part of a multi-organ failure of inflammatory
aetiology, secondary to tumour dissemination; and pneumonitis
for which a causal relationship with saracatinib could not be ruled
out, although other factors for interstitial change were present.
Other possible pneumonitis-like AEs of CTC grade X3 for which
the investigators could not rule out a relationship with saracatinib
were pneumonia (n¼ 1) and lower respiratory tract infection
(n¼ 2).
Response assessment
Objective responses occurred in 5 of the 44 patients (11%) who
received carboplatin plus paclitaxel q3w (primary tumours were
skin (N¼ 2), ovarian (N¼ 2), and breast (N¼ 1)), and 5 of the 24
patients (21%) who received paclitaxel q1w (primary tumours were
ovarian, oesophageal, lung, testes, and cervical). All responses were
partial, and median duration of response was 129 days (range
94–336). The two longest response durations were seen in patients
with ovarian cancer: 336 days (saracatinib 125mg with paclitaxel
q1w) and 245 days (saracatinib 225mg with carboplatin plus
paclitaxel q3w). No objective responses were seen in the
carboplatin q3w group or the paclitaxel q3w group.
Stable disease ofX16 weeks was recorded in 6 of the 44 patients
(14%) who received carboplatin plus paclitaxel q3w, 3 of 21 (14%)
who received carboplatin q3w, 4 of 27 (15%) who received
paclitaxel q3w, and 3 of 24 (13%) who received paclitaxel q1w.
Pharmacokinetics
Geometric mean steady-state PK parameters of saracatinib in Part
B were similar at the end of cycle 1 (saracatinib alone) and at the
beginning of cycle 2 (in combination with carboplatin plus
paclitaxel; Table 4). Geometric mean AUC and Cmax for carboplatin
and paclitaxel in Part B were similar between cycle 1 (chemother-
apy alone) and cycle 2 (in combination with saracatinib; Table 4).
Table 2 Dose escalation and dose-limiting toxicities (first cycle of therapy)
Saracatinib dose, mg
Saracatinib with
CþP q3w (N¼24)
Saracatinib with
C q3w (N¼ 21)
Saracatinib with
P q3w (N¼27)
Saracatinib with
P q1w (N¼ 24)
125 5/7 6/7 3/3 3/3
175 6/11 8/14
 Grade 3 fatigue
 Grade 3 colitis ulcerativea
6/6
 Grade 5 neutropenic sepsis
10/13
225 5/6
 Grade 3 hyponatraemia
— 4/7 6/8
 Grade 3 neutropenia
 Grade 4 febrile neutropenia
250 — — 6/8
 Grade 3 febrile neutropenia
—
300 — — 0/3 —
Abbreviations: C¼ carboplatin; P¼ paclitaxel. Number of evaluable patients/total patients per cohort; bullet points indicate dose-limiting toxicities. aExacerbation of pre-existing
condition.
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DISCUSSION
This was the first clinical study of the Src inhibitor saracatinib
in combination with carboplatin and/or paclitaxel. The trial was
designed to assess the safety, tolerability, and PK of saracatinib, in
combination with carboplatin and/or paclitaxel, to identify regimens
suitable for further evaluation in phase II/III trials. Overall, the
general tolerability profile was acceptable for this heavily pre-treated
population, in which the effects of previous chemotherapy might
contribute to the incidence of AEs such as myelosuppression.
Nevertheless, saracatinib at doses X225mg was associated with
increased incidences of CTC gradeX3 AEs of asthenia and neutro-
penia, compared with dosesp175mg. These effects contributed to
a general overall burden of toxicity at saracatinib doses X225mg,
even though in some chemotherapy combinations, such doses were
deemed tolerable according to the specific DLT and dose-escalation
criteria. The increased general toxicity at higher saracatinib doses
was reflected by an apparent inverse relationship between dose
and duration of treatment, with the caveat that duration of therapy
may also be dependent on the biology of the cancer being treated.
In addition, dose-limiting toxicities such as grade 3 fatigue, although
only noted in one case during the formal DLT period (first cycle),
were seen in a number of cases in subsequent cycles. This highlights
the challenges inherent in phase I trials of molecularly targeted
agents, for which various forms of toxicity may become more
apparent after the first cycle (Postel-Vinay et al, 2011).
Febrile neutropenia/neutropenic sepsis was reported in 5%
of patients overall, all of whom received paclitaxel-containing
Table 3 All-cause adverse events
Part A
Part B Total
Number of patients (%)
Saracatinib
with CþP
q3w (N¼ 24)
Saracatinib
with C
q3w (N¼ 21)
Saracatinib
with P
q3w (N¼27)
Saracatinib
with P
q1w (N¼ 24)
Saracatinib with
CþP q3w
(N¼ 20)
All patients
(N¼ 116)
AEs occurring in X15% of patients overall
Nausea 10 (42) 16 (76) 10 (37) 15 (63) 16 (80) 67 (58)
Fatigue 15 (63) 11 (52) 12 (44) 13 (54) 9 (45) 60 (52)
Decreased appetite 12 (50) 7 (33) 10 (37) 10 (42) 8 (40) 47 (41)
Diarrhoea 10 (42) 6 (29) 7 (26) 11 (46) 9 (45) 43 (37)
Vomiting 8 (33) 9 (43) 7 (26) 8 (33) 9 (45) 41 (35)
Alopecia 10 (42) 2 (10) 9 (33) 6 (25) 13 (65) 40 (34)
Anaemia 10 (42) 7 (33) 4 (15) 7 (29) 11 (55) 39 (34)
Constipation 8 (33) 5 (24) 8 (30) 7 (29) 8 (40) 36 (31)
Pyrexia 8 (33) 7 (33) 5 (19) 4 (17) 9 (45) 33 (28)
Neutropenia 9 (38) 0 0 5 (21) 12 (60) 26 (22)
Rash 6 (25) 2 (10) 3 (11) 9 (38) 5 (25) 25 (22)
Dysgeusia 6 (25) 1 (5) 4 (15) 4 (17) 6 (30) 21 (18)
Abdominal pain 2 (8) 5 (24) 5 (19) 5 (21) 2 (10) 19 (16)
Arthralgia 5 (21) 0 5 (19) 4 (17) 5 (25) 19 (16)
Cough 4 (17) 0 3 (11) 10 (42) 1 (5) 18 (16)
Lethargy 2 (8) 2 (10) 5 (19) 5 (21) 4 (20) 18 (16)
Weight decreased 5 (21) 3 (14) 3 (11) 3 (13) 4 (20) 18 (16)
AEs of CTC grade X3 occurring in X5% of patients overall
Neutropenia 8 (33) 0 0 4 (17) 10 (50) 22 (19)
Fatigue 4 (17) 3 (14) 3 (11) 1 (4) 5 (25) 16 (14)
Anaemia 3 (13) 2 (10) 3 (11) 2 (8) 2 (10) 12 (10)
Hyponatraemia 3 (13) 5 (24) 0 0 1 (5)a 9 (8)
Leucopenia 2 (8) 0 0 0 7 (35) 9 (8)
Asthenia 1 (4) 2 (10) 3 (11) 0 2 (10) 8 (7)
Dyspnoea 1 (4) 2 (10) 1 (4) 2 (8) 0 6 (5)
Hypokalaemia 1 (4) 2 (10) 0 2 (8) 1 (5) 6 (5)
Thrombocytopenia 0 3 (14) 0 0 3 (15) 6 (5)
Abbreviations: C¼ carboplatin; P¼ paclitaxel. aIn Part B, sodium p135mmol l 1 at enrolment was an exclusion criterion.
Table 4 Assessment of potential pharmacokinetic drug interactions
Dosing regime N Cmax/Cmax, ss (ngml
 1) AUC/AUCss (ng.hml
1)
Saracatinib alone 9 590 (38.4) 10600 (43.8)
Saracatinibþ carboplatinþ paclitaxel 9 545 (42.2) 9990 (35.5)
Ratio of saracatinib in combination/alone 9 0.923 (0.675–1.25) 0.940 (0.774–1.23)
Carboplatina without saracatinib 4 33600 (20.4) 64933 (24.8)
Carboplatina in combination with saracatinib 4 36500 (15.5) 73867 (16.0)
Ratio of carboplatina with/without saracatinib 4 1.087 (0.898–1.53) 1.14 (0.921–1.67)
Paclitaxelb without saracatinib 6 2970 (35.4) 9850 (22.8)
Paclitaxelb in combination with saracatinib 6 2840 (22.2) 10100 (20.9)
Ratio of paclitaxelb with/without saracatinib 6 0.957 (0.682–1.82) 1.02 (0.871–1.51)
Abbreviations: AUCss¼ area under the plasma concentration–time curve during any dosing interval at steady state (for saracatinib); AUC¼ area under the plasma
concentration–time curve (for carboplatin and paclitaxel); Cmax, ss¼maximum plasma concentration at steady state (for saracatinib); Cmax¼maximum plasma concentration
(for carboplatin and paclitaxel); N¼ number subjects used to calculate parameters. Parameters are expressed as geometric mean (coefficient of variation, %); ratios are geometric
mean (range). aIn combination with paclitaxel. bIn combination with carboplatin.
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chemotherapy. These events were reported in a considerably
higher proportion of patients in Part B (15%) than in Part A (3%).
Our Part B findings are not dissimilar from the reporting rate of
febrile neutropenia in a randomised phase II study of saracatinib
in combination with carboplatin and paclitaxel: 23% of patients in
the saracatinib arm vs 3% in the placebo arm (Poole et al, 2010).
Most reports of febrile neutropenia in the randomised study
occurred in cycle 1, and the outcome was uncomplicated: events
were not generally associated with infection and did not have fatal
outcomes or complications of organ failure, and repeated episodes
of febrile neutropenia rarely occurred in the same patient (data
on file, AstraZeneca). In our study, the Part B treatment schedule
was similar to that of the randomised study (Poole et al, 2010);
saracatinib treatment started on the same day as, or shortly after
the first chemotherapy infusion, whereas in Part A of our study,
saracatinib treatment started 7–10 days before the first chemother-
apy infusion. A temporally coincident occurrence of paclitaxel-
induced neutropenia and the events of pyrexia attributable to
saracatinib treatment (which occur in the second week of
treatment) might explain the reporting rate of febrile neutropenia.
According to this hypothesis, the saracatinib run-in period may
temporally separate these pyrexic episodes from the paclitaxel-
induced neutropenia, which would otherwise contribute to a
coincidentally exaggerated incidence of febrile neutropenia.
A schedule with a 1-week saracatinib run-in before paclitaxel
chemotherapy is being investigated in an ongoing randomised
placebo-controlled trial in patients with relapsed platinum-resistant
ovarian cancer (clinicaltrials.gov identifier NCT01196741).
An increased incidence of hyponatraemia was observed in
patients receiving saracatinib plus carboplatin, compared with
patients receiving saracatinib plus paclitaxel only. However, the
incidence of hyponatraemia declined substantially after a protocol
amendment was introduced to exclude patients with sodium
p135mmol l 1 at enrolment. Although platinum-based che-
motherapies are known to be associated with hyponatraemia, the
possibility that saracatinib may potentiate the hyponatraemic
effects of carboplatin cannot be ruled out.
The opportunity was taken in Part B of the study to undertake a
limited evaluation of the possibility of drug–drug interactions. On
theoretical grounds, such interactions were not predicted, as the
major clearance pathways of saracatinib, carboplatin and paclitaxel
are different. Saracatinib is thought to be cleared mainly through
metabolism by CYP3A4 (AstraZeneca data on file), whereas
carboplatin is cleared predominantly via the kidney without
metabolism (Elferink et al, 1987). Paclitaxel is cleared by
metabolism, but the major enzyme involved is CYP2C8 (Cresteil
et al, 1994). Furthermore, it has been shown previously that
paclitaxel clearance is not modulated even by the presence of the
very potent CYP3A4 inhibitor ketoconazole (Jamis-Dow et al,
1997). The PK of saracatinib described here are similar to the PK of
saracatinib monotherapy in a previously reported study (Baselga
et al, 2010). Moreover, saracatinib had no apparent effect on the
PK of carboplatin or paclitaxel. Although the numbers are small,
there is no evidence in this study that the exposure of carboplatin
or paclitaxel in patients with solid tumours is affected by the
co-administration of saracatinib. These results support the
prediction and indicate that there is no PK interaction between
saracatinib and carboplatin or paclitaxel.
This phase I study was not designed to assess efficacy, and in the
absence of a control arm, comparisons with other trials and data
sets are problematic. The relatively modest response to carbopla-
tin/paclitaxel in this study might be attributable to the advanced
state of disease in the study population, as evidenced by the large
number of prior chemotherapies. A more thorough assessment of
the efficacy of saracatinib in combination with carboplatin plus
paclitaxel has been made in a recent randomised placebo-
controlled phase II trial in patients with recurrent platinum-
sensitive epithelial ovarian cancer (Poole et al, 2010). The
preliminary analysis indicated no difference in objective response
rate between saracatinib and placebo in combination with
carboplatin plus paclitaxel. However, clinical data suggest that
the impact of saracatinib on chemosensitivity may best be seen in
the context of platinum resistance (Dressman et al, 2007), although
these data are yet to be replicated in large numbers. With the
caveat that the numbers involved are small, the most significant
efficacy in the present study was indeed observed in patients with
platinum-resistant ovarian cancer, including one patient with
ovarian cancer treated with saracatinib and paclitaxel q1w, who
had a partial response lasting 336 days. She had previously been
treated with carboplatin/paclitaxel, doxorubicin HCl liposome,
carboplatin/gemcitabine, and carboplatin/capecitabine, and her
disease was platinum-refractory. That the longest responses were
seen in patients treated with paclitaxel is consistent with in vitro
evidence of potential synergy between Src pathway inhibition and
taxane treatment (Halder et al, 2005; Konecny et al, 2009; Teoh
et al, 2011). The combination of saracatinib with paclitaxel q1w is
currently being examined in a randomised phase II trial in patients
with platinum-resistant ovarian cancer (clinicaltrials.gov identifier
NCT01196741).
In conclusion, our data indicated that saracatinib doses up to
175mg once daily can be given to most patients with acceptable
toxicity in combination with paclitaxel (q1w or q3w) with or
without carboplatin. There was no evidence that the presence
of saracatinib affected exposure to carboplatin or paclitaxel
chemotherapy, or vice versa.
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